Thomas E. Watts, Abhishek J. Deshmukh, Sadip Pant, Juan Viles-Gonzalez and Hakan Paydak
Genomics in Atrial Fibrillation Atrial fibrillation (AF) carries a significant burden in the form of morbidity, mortality, and cost to the healthcare system. According to the Center for Disease Control, AF is the most common cardiac arrhythmia in the United States with an incidence of 2.26 million people in 2010 that is expected to increase to 12 million people by 2050 [1]. The mortality rate from AF as a primary or secondary cause of death is increasing, as is the cost burden to the healthcare system [1]. It is estimated that in the year 2005, the cost to the U.S. healthcare system for treating AF was $6.65 billion
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 